1. Home
  2. GILD vs LOW Comparison

GILD vs LOW Comparison

Compare GILD & LOW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GILD
  • LOW
  • Stock Information
  • Founded
  • GILD 1987
  • LOW 1946
  • Country
  • GILD United States
  • LOW United States
  • Employees
  • GILD N/A
  • LOW N/A
  • Industry
  • GILD Biotechnology: Biological Products (No Diagnostic Substances)
  • LOW RETAIL: Building Materials
  • Sector
  • GILD Health Care
  • LOW Consumer Discretionary
  • Exchange
  • GILD Nasdaq
  • LOW Nasdaq
  • Market Cap
  • GILD 145.4B
  • LOW 135.9B
  • IPO Year
  • GILD 1992
  • LOW N/A
  • Fundamental
  • Price
  • GILD $122.58
  • LOW $234.35
  • Analyst Decision
  • GILD Buy
  • LOW Buy
  • Analyst Count
  • GILD 22
  • LOW 21
  • Target Price
  • GILD $120.90
  • LOW $281.43
  • AVG Volume (30 Days)
  • GILD 6.9M
  • LOW 2.4M
  • Earning Date
  • GILD 10-30-2025
  • LOW 11-19-2025
  • Dividend Yield
  • GILD 2.58%
  • LOW 2.05%
  • EPS Growth
  • GILD 6514.05
  • LOW 0.93
  • EPS
  • GILD 6.42
  • LOW 12.17
  • Revenue
  • GILD $29,087,000,000.00
  • LOW $83,612,000,000.00
  • Revenue This Year
  • GILD $3.05
  • LOW $2.74
  • Revenue Next Year
  • GILD $3.29
  • LOW $6.25
  • P/E Ratio
  • GILD $19.09
  • LOW $19.26
  • Revenue Growth
  • GILD 2.79
  • LOW N/A
  • 52 Week Low
  • GILD $86.08
  • LOW $206.39
  • 52 Week High
  • GILD $124.61
  • LOW $280.64
  • Technical
  • Relative Strength Index (RSI)
  • GILD 61.86
  • LOW 35.13
  • Support Level
  • GILD $114.02
  • LOW $232.98
  • Resistance Level
  • GILD $121.58
  • LOW $246.63
  • Average True Range (ATR)
  • GILD 3.17
  • LOW 4.40
  • MACD
  • GILD 0.07
  • LOW -0.22
  • Stochastic Oscillator
  • GILD 80.83
  • LOW 17.75

About GILD Gilead Sciences Inc.

Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).

About LOW Lowe's Companies Inc.

Lowe's is the second-largest home improvement retailer globally, with around 1,750 stores in the US, after the 2023 divestiture of its Canadian locations (RONA, Lowe's Canada, Réno-Dépôt, and Dick's Lumber). The firm's stores offer products and services for home decorating, maintenance, repair, and remodeling, with maintenance and repair accounting for two-thirds of products sold. Lowe's primarily targets retail do-it-yourself (around 70% of sales) and do-it-for-me customers, but has expanded its professional business clients to 30% from less than 20% in the past six years (set ot expand further with the acquisition of FBM). We estimate Lowe's captures a high-single-digit share of the domestic home improvement market, based on US Census data and management's market size estimates.

Share on Social Networks: